GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhejiang Tianyu Pharmaceutical Co Ltd (SZSE:300702) » Definitions » Piotroski F-Score

Zhejiang Tianyu Pharmaceutical Co (SZSE:300702) Piotroski F-Score : 2 (As of Apr. 29, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Zhejiang Tianyu Pharmaceutical Co Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 2 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Zhejiang Tianyu Pharmaceutical Co has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Zhejiang Tianyu Pharmaceutical Co's Piotroski F-Score or its related term are showing as below:

SZSE:300702' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 4   Max: 8
Current: 2

During the past 10 years, the highest Piotroski F-Score of Zhejiang Tianyu Pharmaceutical Co was 8. The lowest was 1. And the median was 4.


Zhejiang Tianyu Pharmaceutical Co Piotroski F-Score Historical Data

The historical data trend for Zhejiang Tianyu Pharmaceutical Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhejiang Tianyu Pharmaceutical Co Piotroski F-Score Chart

Zhejiang Tianyu Pharmaceutical Co Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 7.00 6.00 1.00 1.00

Zhejiang Tianyu Pharmaceutical Co Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 1.00 3.00 2.00 2.00

Competitive Comparison of Zhejiang Tianyu Pharmaceutical Co's Piotroski F-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Tianyu Pharmaceutical Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhejiang Tianyu Pharmaceutical Co's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zhejiang Tianyu Pharmaceutical Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Zhejiang Tianyu Pharmaceutical Co's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep23) TTM:Last Year (Sep22) TTM:
Net Income was -157.718 + 100.238 + -32.126 + 0.683 = ¥-89 Mil.
Cash Flow from Operations was -94.855 + -63.02 + 11.98 + -86.043 = ¥-232 Mil.
Revenue was 582.284 + 777.214 + 569.175 + 518.57 = ¥2,447 Mil.
Gross Profit was 132.945 + 301.175 + 234.137 + 211.532 = ¥880 Mil.
Average Total Assets from the begining of this year (Sep22)
to the end of this year (Sep23) was
(6294.41 + 6415.75 + 6428.673 + 6348.669 + 6329.655) / 5 = ¥6363.4314 Mil.
Total Assets at the begining of this year (Sep22) was ¥6,294 Mil.
Long-Term Debt & Capital Lease Obligation was ¥158 Mil.
Total Current Assets was ¥2,968 Mil.
Total Current Liabilities was ¥2,567 Mil.
Net Income was -1.368 + 84.721 + 10.228 + -56.184 = ¥37 Mil.

Revenue was 605.175 + 749.898 + 724.036 + 610.46 = ¥2,690 Mil.
Gross Profit was 196.361 + 251.267 + 162.878 + 140.452 = ¥751 Mil.
Average Total Assets from the begining of last year (Sep21)
to the end of last year (Sep22) was
(5558.414 + 5800.602 + 6120.893 + 6302.77 + 6294.41) / 5 = ¥6015.4178 Mil.
Total Assets at the begining of last year (Sep21) was ¥5,558 Mil.
Long-Term Debt & Capital Lease Obligation was ¥116 Mil.
Total Current Assets was ¥3,052 Mil.
Total Current Liabilities was ¥2,388 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Zhejiang Tianyu Pharmaceutical Co's current Net Income (TTM) was -89. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Zhejiang Tianyu Pharmaceutical Co's current Cash Flow from Operations (TTM) was -232. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep22)
=-88.923/6294.41
=-0.0141273

ROA (Last Year)=Net Income/Total Assets (Sep21)
=37.397/5558.414
=0.006728

Zhejiang Tianyu Pharmaceutical Co's return on assets of this year was -0.0141273. Zhejiang Tianyu Pharmaceutical Co's return on assets of last year was 0.006728. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Zhejiang Tianyu Pharmaceutical Co's current Net Income (TTM) was -89. Zhejiang Tianyu Pharmaceutical Co's current Cash Flow from Operations (TTM) was -232. ==> -232 <= -89 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep22 to Sep23
=157.755/6363.4314
=0.02479087

Gearing (Last Year: Sep22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep21 to Sep22
=116.355/6015.4178
=0.0193428

Zhejiang Tianyu Pharmaceutical Co's gearing of this year was 0.02479087. Zhejiang Tianyu Pharmaceutical Co's gearing of last year was 0.0193428. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep23)=Total Current Assets/Total Current Liabilities
=2967.69/2567.291
=1.15596167

Current Ratio (Last Year: Sep22)=Total Current Assets/Total Current Liabilities
=3052.16/2388.36
=1.2779313

Zhejiang Tianyu Pharmaceutical Co's current ratio of this year was 1.15596167. Zhejiang Tianyu Pharmaceutical Co's current ratio of last year was 1.2779313. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Zhejiang Tianyu Pharmaceutical Co's number of shares in issue this year was 350.807. Zhejiang Tianyu Pharmaceutical Co's number of shares in issue last year was 353.897. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=879.789/2447.243
=0.3595021

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=750.958/2689.569
=0.27921128

Zhejiang Tianyu Pharmaceutical Co's gross margin of this year was 0.3595021. Zhejiang Tianyu Pharmaceutical Co's gross margin of last year was 0.27921128. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep22)
=2447.243/6294.41
=0.38879625

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep21)
=2689.569/5558.414
=0.48387346

Zhejiang Tianyu Pharmaceutical Co's asset turnover of this year was 0.38879625. Zhejiang Tianyu Pharmaceutical Co's asset turnover of last year was 0.48387346. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+0+0+0+1+1+0
=2

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Zhejiang Tianyu Pharmaceutical Co has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

Zhejiang Tianyu Pharmaceutical Co  (SZSE:300702) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Zhejiang Tianyu Pharmaceutical Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Zhejiang Tianyu Pharmaceutical Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Zhejiang Tianyu Pharmaceutical Co (SZSE:300702) Business Description

Traded in Other Exchanges
N/A
Address
Chemical Development Zone, Zhejiang Province, Huangyan, Jiangkou, Taizhou, CHN, 318020
Zhejiang Tianyu Pharmaceutical Co Ltd is the pharmaceutical manufacturing company. Its main business is the development, production and sales of active pharmaceutical ingredients and intermediates. The products mainly include antihypertensive drug and intermediates, anti-asthma drug raw materials and intermediates, antiviral drug intermediates. Its products are well sold in domestic and overseas markets.

Zhejiang Tianyu Pharmaceutical Co (SZSE:300702) Headlines

No Headlines